IMRT Usage and Cost Related to Geography And Medicare Reimbursement Policy, Study Finds
Aflibercept Improves Overall Survival In Second-Line Colorectal Cancer Setting
Motesanib Does Not Improve OS; Study Doesn’t Meet Primary Endpoint
Beta Blockers Negate Harmful Recurrence Risks of ACE Inhibitors
Study Validates “PEM” Scans As Biopsy Guidance Method
Prostatectomy Lowers Death Risk Compared to Watchful Waiting
Postponed Surgery For Low-Grade Prostate Cancer Adds No Risk
Acupuncture Can Relieve Side Effects of Hormone Treatment
Selumetinib Displays Positive Results, 60% with Stable Disease
National Health Organizations Warn of Risks in Indoor Tanning
Clinical Trials Approved By NCI CTEP Last Month
SWOG Launching New Study Based on Recurrence Test Scores
Centocor Withdraws Yondelis After FDA Calls for New Study
FDA Approves New Device For Glioblastoma Multiforme
EU Gives Marketing Approval For HBV Sequencing Test
Roche Markets CMV Test in Europe
Trending Stories
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook
- Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship” - Pediatric cancer five-year survival rate has increased dramatically, AACR says in inaugural Pediatric Cancer Progress Report
- Anthony Letai pledges to ensure stability for extramural and intramural cancer science
- Antonio Wolff, Mikala Egeblad named co-directors of Johns Hopkins Kimmel Cancer Center Breast and Gynecologic Cancer Program
